Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
View Patent ↗The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
1. An isolated peptide comprising ALPFGFILV (SEQ ID NO:3).
2. A composition comprising a peptide comprising ALPFGFILV (SEQ ID NO:3) and a physiologically-acceptable earner.
3. The composition of claim 2 , wherein said carrier is a pharmaceutically-acceptable carrier.
4. The composition of claim 2 , further comprising a T-helper epitope consisting essentially of TPPAYRPPNAPIL (SEQ ID NO:5).
5. The composition of claim 2 , further comprising a T-helper epitope comprising TPPAYRPPNAPIL (SEQ ID NO:5).
6. The composition of claim 3 , which is formulated for injection.
7. The composition of claim 6 , which is formulated for parenteral injection.
8. The composition of claim 5 , wherein said carrier is a pharmaceutically-acceptable carrier.
9. The composition of claim 8 , which is formulated for injection.
10. The composition of claim 9 , which is formulated for parenteral injection.